Lessons from the skeleton: Was the Women's Health Initiative (WHI) a primary prevention trial?

Osteoporosis International

Volumn 13, Issue 9, 2002, Pages 685-687

  Kleerekoper, M ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GESTAGEN; RISEDRONIC ACID;

CLINICAL TRIAL; EDITORIAL; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIALS; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTINS; RESEARCH DESIGN; RISK; WOMEN'S HEALTH;

EID: 0036712958     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200094     Document Type: Editorial

References (36)

1. Postmenopausal osteoporosis
2. Sex steroids and the construction and conservation of the adult skeleton
3. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial
4. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
5. Effect of risedronate on the risk of hip fracture in elderly women
6. Effects of hormone replacement therapy on clinical fractures and height loss: The heart and estrogen/progestin replacement study (HERS)
7. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
8. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
9. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects
10. Combined oral oestradiol valeratenorethisterone treatment over three years in postmenopausal women: Correlation between oestrogen levels and bone mineral density sites
11. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone
12. The lack of effect of progestogen on bone
13. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women
14. Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women
15. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women
16. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
17. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study
18. Estrogen replacement therapy and fractures in older women
19. The Nurses' Health Study: 20-Year contribution to the understanding of health among women
20. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture
21. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women
22. Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis
23. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies
24. Menopausal hormone replacement therapy and breast cancer: A meta-analysis
25. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
26. Prospective study of exogenous hormones and risk of pulmonary embolism in women
27. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
28. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
29. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease
30. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)
31. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
32. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up HERS II)
33. The estrogen replacement and atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort
34. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease
35. Age at natural menopause and risk of cardiovascular disease
36. A longitudinal study of the treatment of hot flushes: The population study of women in Gothenburg during a quarter of a century